Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing

Area of Science:

• Oncology
• Biotechnology
• Cancer Research

Background:

• Organoid models are revolutionizing preclinical cancer research, particularly for prostate cancer (PCa).
• Reproducibility in organoid drug testing is hindered by experimental variability.
• PCa organoids show reduced sensitivity to drugs like cabazitaxel, abiraterone, and enzalutamide compared to single cells.

Purpose of the Study:

• To investigate how three-dimensional (3D) organoid organization and scaffolds affect prostate cancer drug efficacy.
• To understand the impact of scaffold type, spatial distribution, and organoid size on treatment response.

Main Methods:

• Live-cell imaging was employed to monitor androgen receptor (AR) nuclear translocation and tubulin stabilization.
• The study analyzed the effects of different 3D scaffolds (Matrigel, synthetic hydrogel), organoid distribution, and organoid size on drug treatment outcomes.

Main Results:

• 3D scaffolds delayed AR translocation and tubulin stabilization, with Matrigel showing a more pronounced delay than synthetic hydrogel.
• Scaffolds led to incomplete tubulin stabilization.
• Central organoid location within scaffolds and larger organoid size attenuated drug effects, particularly in the organoid core.

Conclusions:

• 3D organoid structure and scaffold properties significantly influence drug efficacy in preclinical models.
• Interpreting organoid drug responses requires careful consideration of technical factors like scaffold type, organoid size, and spatial distribution.
• Dedicated read-outs are necessary for accurate and reproducible organoid drug testing in cancer research.